Advertisement

Breast Cancer Research and Treatment

, Volume 174, Issue 1, pp 197–208 | Cite as

Impact of preexisting mental illness on breast cancer endocrine therapy adherence

  • Cole B. HaskinsEmail author
  • Bradley D. McDowell
  • Ryan M. Carnahan
  • Jess G. Fiedorowicz
  • Robert B. Wallace
  • Brian J. Smith
  • Elizabeth A. Chrischilles
Epidemiology
  • 102 Downloads

Abstract

Purpose

Patients with estrogen receptor positive (ER+) breast cancer are often non-adherent to endocrine therapies, despite clear survival benefits. We utilized a nationally representative cancer cohort to examine the role of specific mental illnesses on endocrine therapy adherence.

Methods

Using the SEER-Medicare database, we included 21,894 women aged 68+ at their first surgically treated stage I-IV ER+ breast cancer during 2007–2013. All had continuous fee-for-service Medicare Parts A and B for 36+ months before, 18+ months after diagnosis, and continuous Part D for 4+ months before, 18+ after diagnosis. Mental illness was defined as occurring in the 36 months prior to cancer onset. We analyzed endocrine therapy adherence, initiation, and discontinuation using longitudinal linear and Cox regression models.

Results

Unipolar depression (11.0%), anxiety (9.5%), non-schizophrenia psychosis (4.6%), and dementias (4.6%) were the most prevalent diagnoses. Endocrine therapies were initiated by 80.0% of women. Among those with at least one year of use, 28.0% were non-adherent (< 0.80 adherence, mean = 0.84) and 25.7% discontinued. Patients with dementia or bipolar depression/psychotic/schizophrenia disorders had lower adjusted initiation probabilities by year one of follow-up, versus those without these diagnoses [0.74 95% CI (0.73–0.74) and 0.73 (0.72–0.73), respectively, reference 0.76 (0.76–0.77)]. Patients with substance use or anxiety disorders less frequently continued endocrine therapy for at least one year, after adjustment, [0.85 95% CI (0.85–0.86) and 0.88 (0.87–0.88), respectively, reference 0.90 (0.89–0.90)]. Patients with substance use disorders had 2.3% lower adherence rates (p < 0.001).

Conclusions

Nearly one-quarter of female Medicare beneficiaries have diagnosed mental illness preceding invasive breast cancer. Those with certain mental illnesses have modestly reduced rates of initiation, adherence, and discontinuation and this may help define patients at higher risk of treatment abandonment. Overall, endocrine therapy adherence remains suboptimal, unnecessarily worsening recurrence and mortality risk.

Keywords

Preexisting mental illness Endocrine therapy Adherence SEER-Medicare 

Notes

Acknowledgements

This work was supported by the University of Iowa Holden Comprehensive Cancer Center Population Research Core (P30 CA086862), and the University of Iowa Medical Scientist Training Program (T32 GM007337). This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development, and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement # U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development, and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.

Compliance with ethical standards

Conflict of interest

Dr. Fiedorowicz reports a consultation role with Myriad Genetics, Inc. (consultation for mood disorder proteomics study), as well as research funding from Myriad Genetics, Inc. (not applied to this work). Mr. Haskins, and Drs. McDowell, Carnahan, Wallace, Smith, and Chrischilles have no disclosures or conflict of interest to report.

Ethical standards

This study did not involve any direct human interventions. All research and analysis was performed in compliance with the current University of Iowa IRB regulations and laws of the United States.

References

  1. 1.
    Davies C et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816CrossRefGoogle Scholar
  2. 2.
    Partridge AH et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606CrossRefGoogle Scholar
  3. 3.
    Hershman DL et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128CrossRefGoogle Scholar
  4. 4.
    Doggrell SA et al (2011) Adherence to oral endocrine treatments in women with breast cancer: can it be improved? Breast Cancer Res Treat 129(2):299–308CrossRefGoogle Scholar
  5. 5.
    Hershman DL et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537CrossRefGoogle Scholar
  6. 6.
    Hadji P et al (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73(2):156–166CrossRefGoogle Scholar
  7. 7.
    Land SR et al. (2016) Symptoms and QOL as predictors of chemoprevention adherence in NRG oncology/NSABP trial P-1. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djv365 Google Scholar
  8. 8.
    Mausbach BT et al (2015) Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 152(2):239–246CrossRefGoogle Scholar
  9. 9.
    Iglay K et al (2017) Diagnosis and treatment delays among elderly breast cancer patients with pre-existing mental illness. Breast Cancer Res Treat 166(1):267–275CrossRefGoogle Scholar
  10. 10.
    Iglay K et al (2017) Impact of preexisting mental illness on all-cause and breast cancer-specific mortality in elderly patients with breast cancer. J Clin Oncol 35(36):4012–4018CrossRefGoogle Scholar
  11. 11.
    Howlader N at al (2017) SEER cancer statistics review, 1975–2014. National Cancer Institute, RockvilleGoogle Scholar
  12. 12.
    NIH. SEER-medicare: SEER program and data. NIH Healthcare Delivery Research Program 2018. https://healthcaredelivery.cancer.gov/seermedicare/aboutdata/program.html
  13. 13.
    NIH. SEER-medicare: medicare claims files. NIH Healthcare Delivery Research Program 2018. https://healthcaredelivery.cancer.gov/seermedicare/medicare/claims.html#part_d
  14. 14.
    NIH. Breast Schema for 1988 + based on AJCC 6th edition. NIH Surveillance, Epidemiology, and End Results Program 2018. https://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th/breast.html
  15. 15.
    NIH. NCI Comorbidity Index Overview. NIH Healthcare Delivery Research Program 2018. https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html
  16. 16.
    American Psychiatric Association (1994) Diagnostic and statistical manual, 6th edn. American Psychiatric Association, Washington DCGoogle Scholar
  17. 17.
    Tajeu GS et al (2016) Trends in antihypertensive medication discontinuation and low adherence among medicare beneficiaries initiating treatment from 2007 to 2012. Hypertension 68(3):565–575CrossRefGoogle Scholar
  18. 18.
    Burstein HJ et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255–2269CrossRefGoogle Scholar
  19. 19.
    Hess LM et al (2006) Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 40(7–8):1280–1288CrossRefGoogle Scholar
  20. 20.
    Chang A et al (2015) A SAS macro to calculate the PDC adjustment of inpatient stays. SAS Global Forum Proceedings 2015. Paper 3560Google Scholar
  21. 21.
    NIH. SEER-medicare: calculation of comorbidity weights. NIH Healthcare Delivery Research Program 2018. https://healthcaredelivery.cancer.gov/seermedicare/considerations/calculation.html
  22. 22.
    Akaike H (1981) Likelihood of a model and information criteria. J Econometr 16:3CrossRefGoogle Scholar
  23. 23.
    Zhang X et al (2007) A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model (vol 88, pg 95, 2007). Computer Methods and Programs in Biomedicine 88(3):313–314CrossRefGoogle Scholar
  24. 24.
    Pan W (2001) Akaike’s information criterion in generalized estimating equations. Biometrics 57(1):120–125CrossRefGoogle Scholar
  25. 25.
    Insel KC et al (2006) The negative association of independent personality and medication adherence. J Aging Health 18(3):407–418CrossRefGoogle Scholar
  26. 26.
    Arlt S et al (2008) Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging 25(12):1033–1047CrossRefGoogle Scholar
  27. 27.
    Reus VI (2015) In: Kasper D (ed) Mental disorders, in Harrison’s principles of internal medicine, 19e. McGraw-Hill Education: New YorkGoogle Scholar
  28. 28.
    Lingam R, Scott J (2002) Treatment non-adherence in affective disorders. Acta Psychiatr Scand 105(3):164–172CrossRefGoogle Scholar
  29. 29.
    De Hert M et al (2011) Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10(2):138–151CrossRefGoogle Scholar
  30. 30.
    Cruz ES et al (2014) Medical rehabilitation—substance abuse, in current diagnosis and treatment: physical medicine and rehabilitation. McGraw-Hill, New YorkGoogle Scholar
  31. 31.
    Leonard S et al (2001) Smoking and mental illness. Pharmacol Biochem Behav 70(4):561–570CrossRefGoogle Scholar
  32. 32.
    Reus VI (2017) In: Jameson JL et al (eds) Psychiatric disorders, in Harrison’s principles of internal medicine, 20e. McGraw-Hill Education: New YorkGoogle Scholar
  33. 33.
    Marion D (2017) Psychological factors affecting other medical conditions: clinical features, assessment, and diagnosis, in uptodate. WalthamGoogle Scholar
  34. 34.
    Hudani ZK, Rojas-Fernandez CH (2016) A scoping review on medication adherence in older patients with cognitive impairment or dementia. Res Soc Adm Pharm 12(6):815–829CrossRefGoogle Scholar
  35. 35.
    Rizzuto D et al (2017) Personality and survival in older age: the role of lifestyle behaviors and health status. Am J Geriatr Psychiatry 25(12):1363–1372CrossRefGoogle Scholar
  36. 36.
    American College of Obstetricians and Gynecologists (2015) Committee Opinion No. 633: Alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice. Obstet Gynecol 125(6):1529-1537CrossRefGoogle Scholar
  37. 37.
    Chapter 2: culture counts: the influence of culture and society on mental health. US Department of Health and Human Services. Mental health: culture, race, ethnicity—a supplement to mental health: a report of the surgeon general. 2001Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Epidemiology, College of Public HealthUniversity of IowaIowa CityUSA
  2. 2.Medical Scientist Training ProgramUniversity of IowaIowa CityUSA
  3. 3.Holden Comprehensive Cancer CenterUniversity of IowaIowa CityUSA
  4. 4.University of Iowa Hospitals and ClinicsIowa CityUSA
  5. 5.Department of Biostatistics, College of Public HealthUniversity of IowaIowa CityUSA

Personalised recommendations